Finnish drug delivery technology and drug development company DelSiTech Ltd has appointed Mrs. Pia Nelimarkka as Director and Head of Product Development, effective as of January, 2019.
Mrs. Nelimarkka, a pharmacist by training and an R&D expert has extensive professional experience in CMC as a former longtime Development and Sourcing Manager at mid-sized Finnish pharmaceuticals company, Orion Pharma. Mrs. Nelimarkka is a specialist in proprietary product development, with exceptional expertise in oncological and CNS therapeutic indications, and with almost 20 years of leading industry experience.
“We are very pleased to welcome Mrs. Nelimarkka into the growing team of drug development professionals in DelSiTech. Her expertise in CMC development will contribute to our ongoing growth and sustainability, especially as our own in-house projects are progressing rapidly, but also for continued diligence to our partners”, said Dr. Lasse Leino, CEO at DelSiTech Ltd.
In a recent interview, Mrs. Nelimarkka was asked to comment on long acting drug delivery solutions, particularly silica matrix technology platforms:
“Biodegradable, silica-based drug delivery is the controlled release technology of the future. I see tremendous opportunities for the technology in therapy efficacy and patient compliance, but critically also for treatment in low-income countries. I am excited and honored to join this team of true experts and enthusiasts at DelSiTech and look forward to lending my expertise on streamlining for our product development pipeline”, said Pia Nelimarkka, Head of Product Development at DelSiTech Ltd.